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Autologous fat transplantation is a common and ideal technique for soft-tissue augmen-tation and for filling soft-tissue defects due 
to its minimal tissue reaction and easy availability. 
However, although this technique follows standard-
ized protocols, there is a relatively high resorption 
rate of the fat graft, the long-term graft survival is 
unpredictable, thus the desired effect is not always 
achieved. It has been observed in long-term follow-
up studies that 20–80% of the graft volume is lost.1
The fat graft survival depends on microenviron-
ment, and a dynamic remodeling after fat graft was 
well received by the recipient site, but the mecha-
nisms of tissue revascularization/regeneration and 
subsequent absorption/fibrosis of the graft are not 
yet completely understood.
Quality and amount of revascularization are the 
key points for graft survival. After autologous fat 
transplantation, the increased resorption and in-Copyright © 2015 The Authors. Published by Wolters Kluwer 
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Background: The increased resorption and the difficulty of the fat graft take following autologous fat 
transplantation procedure are associated with reduced fat tissue revascularization and increased apop-
tosis of adipose cells. We suppose that the lipofilling procedure induces an inflammatory environment 
within the fat graft mass, whose evolution influences the efficacy of autologous fat graft survival. Eryth-
ropoietin (EPO) is a glycoprotein hormone known to exert angiogenetic and anti-inflammatory effects; 
therefore, our purpose was to investigate its reaction with adipose tissue used in lipofilling.
Methods: Fat masses were harvested using manual suction lipectomy and then seeded on dishes in ap-
propriate culture and treated for 3 weeks with 3 doses of EPO. CD31 and CD68 immunohistochemistry 
was used to identify microvessels and several infiltrating leukocyte cells.
Results: Following EPO administration, we have detected an increase in the number of CD31-positive 
microvessel endothelium cells and CD31-positive small leukocytes and a reduction of CD68-positive cells. 
These effects were more conspicuous following higher EPO dose.
Conclusions: Our findings evidence EPO treatment as a useful strategy to sustain the revasculariza-
tion of grafted tissue and to reduce its inflammatory state. (Plast Reconstr Surg Glob Open 2015;3:e338; 
doi:10.1097/GOX.0000000000000305; Published online 30 March 2015.)
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creased apoptosis of adipose cells are direct conse-
quences of poor revascularization.2 Besides, some 
clinical and experimental studies have reported con-
tinuing volume loss of the grafted adipose cells even 
after the grafts appeared revascularized.3
Several studies have documented the production 
of inflammatory cytokines by adipose tissue. Their oc-
currence depends not only on macrophage cells nor-
mally present in the adipose tissue mass, but a large 
amount of this production may directly depend on 
the preadipocytes, which have been observed to be 
able also to produce monocyte chemoattractant pro-
tein-1 and macrophage migration inhibitory factors.4
Based on these findings, we suppose that lipo-
filling procedure induces an inflammatory envi-
ronment within the fat graft mass, whose evolution 
influences the autologous fat graft take.
Erythropoietin (EPO) is a glycoprotein hormone 
that was first characterized by its ability to stimulate 
erythropoiesis. In following researches, it has been 
discovered that EPO is also involved in angiogenesis 
induction: instigating the secretion of angiogenic 
factors, enhancing the immune response, and exert-
ing anti-inflammatory effects.5
Our purpose was to investigate the effect of EPO 
on adipose mass used in lipofilling, focusing mainly 
on the effects on tissue revascularization and the in-
fluence on immune cell behavior.
MATERIALS AND METHODS
Fat graft was harvested using manual suction li-
pectomy under general anesthesia from 10 women, 
41 ± 4 years old, during procedures of reconstructive 
surgery. The participants gave written informed con-
sent. The fat was harvested using a 14-gauge blunt 
cannula and centrifuged at 1500 rpm for 2 minutes.
The fat mass was seeded on dishes in  appropriate 
culture on average for 24 hours and then treated 
for 3 weeks with 3 different doses of EPO (EPREX, 
Janssen-Cilag, Milan, Italy): 0.15, 0.30, and 0.60 μg/ml. 
A positive control was performed administering a 
cocktail of trophic drugs (biotin, T3, pantothenate, 
hydrocortisone, and insulin; from Sigma, St. Louis, Miss.). 
The negative control was left without any treatment.
At the end of this phase, the fat mass was fixed 
in formalin and processed for paraffin inclusion and 
cutting: the obtained 5-μm-thick slides were stained 
with CD31 (to identify active vessels and immune sys-
tem cells) and CD68 (to identify macrophages).
Quantification of cell infiltration in the fat grafts 
was estimated by counting the number of positive 
vessels and cells. To avoid counting bias, due to the 
change of adipocytes diameter, the counting data 
were referred to tissue fat mass of 80 adipocytes. Para-
metric statistical analysis was obtained with Prism5.0 
(GraphPad Software, San Diego, Calif.).
RESULTS
The study of the fat mass cultured under micro-
scope evidenced 3 different zones in respect of adipo-
cytes dimension, extracellular matrix deposition, and 
vessels density. These zones are identified as follow:
Zone 1: wide presence of extracellular matrix, small 
adipocytes (686.3 ± 33.2 μm2), presence of large 
microvessels, and few capillary vessels.
Zone 2: appreciable presence of extracellular ma-
trix, large adipocytes (4573.4 ± 162.3 μm2), and 
presence of capillary vessels.
Zone 3: poor occurrence of extracellular matrix, 
very large adipocytes (12359.6 ± 347.6 μm2), and 
presence of capillary vessels.
Our data were referred specifically to the identi-
fied zones.
Vessels count has evidenced no changes in the 
number of CD31-positive and CD31-negative vessels 
in zone 1 and zone 3 between the different experi-
mental groups analyzed. Differently, zone 2 that has 
been treated with a higher dose of EPO showed a 
higher number of CD31-positive vessels in compari-
son to other experimental groups (Fig. 1).
The CD31-positive cells count showed the occur-
rence of 2 cell populations named small cells (22.3 ± 1.1 
μm2; morphologically compatible with helper lympho-
cytes) and intermediate cells (68.5 ± 6.1 μm2; morpho-
logically compatible with cytotoxic and natural killer 
lymphocytes). The positive control group showed a 
reduction of the number of CD31-positive cells com-
pared with the negative control group. Differently, 
EPO treatment showed an increase in the number of 
small cells and a light decrease of intermediate cell 
number in all the 3 zones (Fig. 2).
The CD68-positive cells count showed the occur-
rence of 2 cell populations named very large cells 
(247.1 ± 15.2 μm2; morphologically compatible with 
macrophages) and large cells (129.2 ± 9.3 μm2; mor-
phologically compatible with B-lymphocytes). In 
comparison to the negative control, the positive con-
trol group exhibits a reduction of CD68-positive cell 
number in zone 2 and zone 3, whereas all EPO treat-
ments showed reduction of very large cell number in 
all zones examined and a reduction of large cells in 
zone 3. Following higher EPO dose treatment, the 
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very large cells reduction was proportionally more 
evident (Figs. 3 and 4).
DISCUSSION
There is a wide presence of inflammatory cells 
in adipose mass extracted for refilling, suggesting 
the potential of the fat mass to produce an inflam-
matory response.
EPO is a well-known factor able to induce tissue 
revascularization. EPO receptors have been found 
in several human leukocytes; therefore, researchers 
supposed that the EPO receptors have a role in mod-
ulating some signaling pathways.6
Our findings clearly remark the provascular 
properties of EPO. Specifically, we observed EPO to 
induce an increase in the number of CD31-positive 
microvessels. CD31 reactivity is a well-known marker, 
indicating the functional activation of microvessels in 
the tissue; therefore, several CD31-negative microves-
sels observed in culture should be interpreted as 
Fig. 1. Bar graph showing results of the morphometrical analysis performed on cd31- 
positive or cd31-negative microvessels detected in zone 2 of the fat mass. aP < 0.05 vs neg; 
bP < 0.05 vs Pos; cP < 0.05 vs epo 0.15; dP < 0.05 vs epo 0.30. epo indicates erythropoietin 
 administration; neg, negative control with no treatment; Pos, positive control treated with 
the cocktail of trophic drugs (see Materials and Methods section).
Fig. 2. Bar graph showing results of the morphometrical analysis performed on cd31-posi-
tive cells of zone 2, detected in the fat mass.
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Fig. 3. Bar graph showing results of the morphometrical analysis performed on cd68-posi-
tive cells of zone 3, detected in the fat mass.
Fig. 4. Microphotograph panels showing the immunohistochemical positive signals occurring in the fat mass. cd68 
immunohistochemistry.
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quiescent microvessels. In addition, EPO presents a 
direct effect on tissue infiltrating leukocytes. The re-
duction of macrophage number is an important find-
ing that may evidence a reduced inflammatory state, 
with macrophages being the principal cells involved 
in the tissue inflammatory pathways. Other significant 
evidence is the increase of CD31-positive small lym-
phocytes. In the absence of a more detailed analysis, 
the increase of the number of lymphocytes can be 
imputed only to a shift of cellular physiology from a 
nonactive state to an active state.
Small lymphocytes widely participate in the in-
flammatory phenomena; on the other hand, they are 
also involved in the release of tissue trophic factors.7 
These findings may indicate lymphocytes as crucial 
cells in supporting the tissue survival and they may 
also be at the origin of the observed reparative ef-
fects detected on skin lesions and bone fractures.8,9
CONCLUSION
In conclusion, EPO treatment may be a useful 
strategy to reduce the inflammatory state of adipose 
grafted tissue and to sustain its revascularization.
Further studies are required to analyze the ex-
tent of graft tissue damage related to inflammatory 
response and which pattern of cytokines is involved 
in modulating the inflammatory response. We think 
that a controlled inflammatory response may be use-
ful to obtain a higher and more predictable survival 
rate in fat transplantation.
Optimizing the fat tissue graft take may lead to a 
reduction in the number of procedures required to 
obtain the desired outcome and thus improving the 
cost/benefit rate. 
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